Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jul 21, 2021 in Breast cancer | 0 comments

In a nutshell

This study was carried out to examine the safety and effectiveness of pyrotinib (Irene) in combination with vinorelbine (Navelibine) is in treating metastatic breast cancer (BC). The authors found that this treatment combination showed promising results and was well tolerated in these patients. 

Some background

BC is one of the most common forms of cancer found in women. Metastatic BC has spread around the body. MBC is difficult to treat and is often resistant to many forms of existing treatment. This creates a demand for new treatments. 

HER2 is a protein found on some BC cells. This protein makes the BC cells resistant to different forms of treatment. HER2+ BC is often difficult to treat and can spread easily. Pyrotinib is a new targeted therapy. It targets the HER2 protein and stops cancer cells from growing and spreading. It is commonly used with chemotherapy drugs such as capecitabine (Xeloda). Vinorelbine is another chemotherapy drug that is effective in MBC and is well tolerated. However, the safety and effectiveness of combining pyrotinib with vinorelbine in patients with HER2-positive BC are still unknown.  

Methods & findings

This study included 97 patients with HER2-positive MBC. All patients were treated with vinorelbine and pyrotinib. 67% of patients had previously received 2 or more different treatments for MBC. The average follow-up for this trial was 8.7 months. 

Overall, 34.3% of patients responded to treatment. The average survival without disease progression was 7.8 months. Patients who received one line of treatment before had an average survival without disease progression of 12 months. Patients who received 2 previous treatments had an average survival without disease progression of 6.4 months. 

The most common side effects were diarrhea (22.7%), and low white blood cell counts (4.1%). 

The bottom line

The authors found that the combination of pyrotinib and vinorelbine had promising effects and was well tolerated in patients with HER2-positive MBC.

The fine print

The study was carried out in a Chinese population so might not translate well to a worldwide population. The study had a very small number of participants and a short follow-up period. It also did not have a comparison group. Further studies are needed.

Published By :

Frontiers in oncology

Date :

May 18, 2021

Original Title :

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.

click here to get personalized updates